CSL Limited has been sued for a breach of patent in the USA, with Bioverativ launching a case against CSL Behring on Friday.
Bioverativ is claiming CSL has "actively breached" patents relating to haemophilia therapy Idelvion, which Bioverativ says breaches a patent on its Alprolix.
CSL said it was "highly confident of its intellectual property position for Idelvion" which was one of its best performers after rapid uptake by patients and doctors.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Jul 17
